TY  - JOUR
AU  - Ugurel, Selma
AU  - Abu Rached, Nessr
AU  - Gambichler, Thilo
AU  - Mengoni, Miriam
AU  - Tüting, Thomas
AU  - Hassel, Jessica C
AU  - Reschke, Robin
AU  - Lodde, Georg C
AU  - Placke, Jan-Malte
AU  - Schadendorf, Dirk
AU  - Reinhardt, Lydia
AU  - Kreuter, Alexander
AU  - Gschnell, Martin
AU  - Utikal, Jochen
AU  - Erdmann, Michael
AU  - Dücker, Pia
AU  - Helbig, Doris
AU  - Franklin, Cindy
AU  - Gebhardt, Christoffer
AU  - Poch, Gabriela
AU  - Kähler, Katharina C
AU  - Weichenthal, Michael
AU  - Gutzmer, Ralf
AU  - Heinzerling, Lucie
AU  - Weishaupt, Carsten
AU  - Mohr, Peter
AU  - Thoms, Kai-Martin
AU  - Lang, Berenice
AU  - Schilling, Bastian
AU  - Haferkamp, Sebastian
AU  - Sachse, Michael
AU  - Welzel, Julia
AU  - Jochims, Franziska
AU  - Raap, Ulrike
AU  - Schley, Gaston
AU  - Terheyden, Patrick
AU  - Dippel, Edgar
AU  - Pöttgen, Christoph
AU  - Becker, Jürgen C
AU  - Tasdogan, Alpaslan
AU  - Amaral, Teresa
AU  - Nanz, Lena
AU  - Leiter, Ulrike
TI  - Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.
JO  - European journal of cancer
VL  - 228
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-01861
SP  - 115750
PY  - 2025
AB  - For rare skin cancers, few data exist on the outcome of systemic therapies, particularly immune checkpoint inhibition (ICI). The present study analysed the real-world use of different systemic therapies including ICI, and its outcome in patients with advanced rare skin cancers.This retrospective multicenter study included patients who received systemic therapy for advanced, non-resectable cutaneous angiosarcoma (AS), Kaposi sarcoma (KS), pleomorphic dermal sarcoma (PDS), or cutaneous adnexal carcinoma (CAC). Study endpoints were best overall response (BOR), progression-free survival (PFS) and overall survival (OS).209 patients (77 AS; 81 KS; 14 PDS; and 37 CAC) from 30 centers were included. As first-line treatment AS and KS patients predominantly received chemotherapy (77.9 
KW  - Angiosarcoma (Other)
KW  - Chemotherapy (Other)
KW  - Cutaneous adnexal carcinoma (Other)
KW  - Immune checkpoint inhibition (Other)
KW  - Kaposi sarcoma (Other)
KW  - Pleomorphic dermal sarcoma (Other)
KW  - Targeted therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40912056
DO  - DOI:10.1016/j.ejca.2025.115750
UR  - https://inrepo02.dkfz.de/record/304468
ER  -